MATINAS BIOPHARMA HOLDINGS, INC. Proceeds from Common Stock Issued
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Proceeds from Common Stock Issued of $9.18 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-03-31
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from issuance of common stock for the quarter ending 2024-12-31 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from issuance of common stock for the quarter ending 2024-09-30 was -$65.00K.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from issuance of common stock for the quarter ending 2024-06-30 was $9.19M.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from issuance of common stock for the quarter ending 2024-03-31 was $54.00K.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from issuance of common stock for fiscal 2024 was $9.18M.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from issuance of common stock for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from issuance of common stock for fiscal 2015 was $10.00M.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from issuance of common stock for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
| Period end | Proceeds from Issuance of Common Stock | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 3 month as first filed | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 6 month as first filed | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed | Proceeds from Issuance of Common Stock 32 month |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$65.00K derived: sum of 2 quarters · filed 2026-03-31 | $9.13M derived: sum of 3 quarters · filed 2026-03-31 | $9.18M 10-K · filed 2026-03-31 | |||||
| 2024-09-30 | -$65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $9.13M derived: sum of 2 quarters · filed 2025-11-10 | $9.18M 10-Q · filed 2025-11-10 | ||||||
| 2024-06-30 | $9.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $9.24M 10-Q · filed 2025-08-14 | |||||||
| 2024-04-05 | $9.19M 10-Q · filed 2024-11-13 | ||||||||
| 2024-03-31 | $54.00K 10-Q · filed 2025-05-15 | ||||||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $0.00 derived: sum of 2 quarters · filed 2017-03-31 | $0.00 derived: sum of 3 quarters · filed 2017-03-31 | $0.00 10-K · filed 2017-03-31 | |||||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $0.00 derived: sum of 2 quarters · filed 2016-11-14 | $0.00 10-Q · filed 2016-11-14 | $0.00 derived: sum of 4 quarters · filed 2018-03-16 | |||||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $0.00 10-Q · filed 2016-08-15 | $0.00 derived: sum of 3 quarters · filed 2018-03-16 | $1.48M derived: sum of 4 quarters · filed 2018-03-16 | |||||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-13 | $0.00 derived: sum of 2 quarters · filed 2018-03-16 | $1.48M derived: sum of 3 quarters · filed 2018-03-16 | $5.72M derived: sum of 4 quarters · filed 2018-03-16 | |||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $1.48M derived: sum of 2 quarters · filed 2018-03-16 | $5.72M derived: sum of 3 quarters · filed 2018-03-16 | $10.00M 10-K · filed 2018-03-16 | $8.51M 10-K · filed 2016-03-30 | ||||
| 2015-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $5.72M derived: sum of 2 quarters · filed 2016-11-14 | $10.00M 10-Q · filed 2016-11-14 | $10.00M derived: sum of 4 quarters · filed 2016-11-14 | |||||
| 2015-06-30 | $4.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $8.52M 10-Q · filed 2016-08-15 | $10.00M 10-Q · filed 2015-08-13 | $8.52M derived: sum of 3 quarters · filed 2016-08-15 | $8.52M derived: sum of 4 quarters · filed 2016-08-15 | ||||
| 2015-03-31 | $4.28M 10-Q · filed 2016-05-13 | $4.94M 10-Q · filed 2015-05-15 | $4.28M derived: sum of 2 quarters · filed 2016-05-13 | $4.28M derived: sum of 3 quarters · filed 2016-05-13 | $4.28M derived: sum of 4 quarters · filed 2016-05-13 | ||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $0.00 derived: sum of 2 quarters · filed 2016-03-30 | $0.00 derived: sum of 3 quarters · filed 2016-03-30 | $0.00 10-K · filed 2016-03-30 | |||||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $0.00 derived: sum of 2 quarters · filed 2015-11-10 | $0.00 10-Q · filed 2015-11-10 | $0.00 derived: sum of 4 quarters · filed 2015-11-10 | |||||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $0.00 10-Q · filed 2015-08-13 | $0.00 derived: sum of 3 quarters · filed 2015-08-13 | ||||||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-15 | $0.00 derived: sum of 2 quarters · filed 2015-05-15 | $15.00M 10-Q · filed 2014-06-06 | ||||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $15.00M 10-K · filed 2015-03-31 | |||||||
| 2013-09-30 | $15.00M 10-Q · filed 2014-11-14 | ||||||||
| 2013-03-31 | $0.00 10-Q · filed 2014-06-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |